Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal down13.840 -0.180 (-1.284%)
Research Report

26/01/2021 14:54

{I-bank focus}Morgan lifts CMS (00867) to HK$14.3

[ET Net News Agency, 26 January 2021] Morgan Stanley lifted its target price for China
Medical System (CMS) (00867) to HK$14.3 from HK$12.5 and maintained its "overweight"
rating as its valuation looks attractive.
The research house raised its 2020 and outer-year forecasts to reflect the contributions
from health-related products, such as Plenity.
Morgan said CMS is the leading Chinese in-licensing entrant and has solid know-how in
drug in-licensing. It has six blockbuster drugs and seven in-licensed generics that could
hit the Chinese market during 2021-23.
CMS has a well-established sales network, leveraging on external R&D. The recovery looks
sustainable in view of the accelerating growth of key products and a more benign
centralized procurement policy. (KL)

Remark: Real time quote last updated: 27/09/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.